Do you believe that we need new tools in our HIV prevention toolbox? At the HIV Prevention Justice Alliance, we support broad and strategic research to explore new methods and interventions for HIV prevention.
Like many of you, we were intrigued by the results of the iPrex trial of pre-exposure prophylaxis (PrEP) that came out late last year. The U.S. Food and Drug Administration (FDA) should review those results and determine if PrEP is safe and effective enough to be approved for widespread use.
Unfortunately, a key HIV health care provider is asking the FDA to deny this choice to gay men and transgender people across the United States.
Sign this letter as individuals and/or organizations to support immediate FDA review of PrEP.
The iPrEx trial showed that daily use of the treatment pill TDF/FTC (brand name Truvada) as part of a comprehensive prevention package reduced the risk of HIV infection by 44 percent across the whole group of gay men, other men who have sex with men (MSM) and transgender women who have sex with men (TSM) who volunteered in the study. Half of that group received Truvada and half did not in order to compare whether its use made a difference.
44% may not seem like a home run, but it can have a powerful impact for the people who need it. It's well within the accepted range for many widely used prevention interventions and medical treatments – and could be the first step towards a true advance in HIV prevention. And it's much better than 0% protection for folks who are unable to use condoms, for whatver reason.
ShareThis 
